Amgen (AMGN) said new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showed Prolia injection reduced fracture risk in patients versus oral alendronate.
Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment
Longer Duration of Treatment With Prolia Was Associated. | May 8, 2023
"The situation and the risk are being seen as moderate," WHO spokesperson Tarik Jasarevic told reporters at a briefing in Geneva. Amgen sues Novartis to block generic osteoporosis, bone cancer drugs Amgen Inc sued Novartis AG's Sandoz in New Jersey federal court Monday, accusing Sandoz's proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.
GSG-7 delivers GNSS signal testing in a cost-effective, turnkey form factor supporting the growing need for location-aware applications; Webinar Scheduled Oct 6
/PRNewswire/ After an exclusive negotiation process that began in December 2021, Orolia a company recognized globally for its positioning, navigation and.